UCLA

UCLA Previously Published Works

Title

Gene Networks and Pathways for Plasma Lipid Traits via Multi-tissue Multi-omics Systems Analysis.

Permalink

<https://escholarship.org/uc/item/8x4699qd>

Authors

Blencowe, Montgomery
Ahn, In Sook
Saleem, Zara
et al.

Publication Date

2020-12-23

DOI

10.1194/jlr.ra120000713

Peer reviewed

Gene networks and pathways for plasma lipid traits via multitissue multiomics systems analysis

Montgomery Blencowe^{1,2,*}, In Sook Ahn^{1,*}, Zara Saleem¹, Helen Luk¹, Ingrid Cely¹, Ville-Petteri Mäkinen^{1,3}, Yuqi Zhao^{1,*}, and Xia Yang^{1,2,4,*}

¹Department of Integrative Biology and Physiology and ²Molecular, Cellular, and Integrative Physiology Interdepartmental Program, University of California, Los Angeles, Los Angeles, CA, USA; ³South Australian Health and Medical Research Institute, Adelaide, Australia; and ⁴Interdepartmental Program of Bioinformatics, University of California, Los Angeles, Los Angeles, CA, USA

Abstract Genome-wide association studies (GWASs) have implicated ~380 genetic loci for plasma lipid regulation. However, these loci only explain 17–27% of the trait variance, and a comprehensive understanding of the molecular mechanisms has not been achieved. In this study, we utilized an integrative genomics approach leveraging diverse genomic data from human populations to investigate whether genetic variants associated with various plasma lipid traits, namely, total cholesterol, high and low density lipoprotein cholesterol (HDL and LDL), and triglycerides, from GWASs were concentrated on specific parts of tissue-specific gene regulatory networks. In addition to the expected lipid metabolism pathways, gene subnetworks involved in “interferon signaling,” “autoimmune/immune activation,” “visual transduction,” and “protein catabolism” were significantly associated with all lipid traits. In addition, we detected trait-specific subnetworks, including cadherin-associated subnetworks for LDL; glutathione metabolism for HDL; valine, leucine, and isoleucine biosynthesis for total cholesterol; and insulin signaling and complement pathways for triglyceride. Finally, by using gene-gene relations revealed by tissue-specific gene regulatory networks, we detected both known (e.g., *APOH*, *APOA4*, and *ABCA1*) and novel (e.g., *F2* in adipose tissue) key regulator genes in these lipid-associated subnetworks. Knockdown of the *F2* gene (coagulation factor II, thrombin) in 3T3-L1 and C3H10T1/2 adipocytes altered gene expression of *Abcb11*, *Apoa5*, *ApoJ*, *Fabp1*, *LipC*, and *Cd36*; reduced intracellular adipocyte lipid content; and increased extracellular lipid content, supporting a link between adipose thrombin and lipid regulation. Our results shed light on the complex mechanisms underlying lipid metabolism and highlight potential novel targets for lipid regulation and lipid-associated diseases.

Supplementary key words lipid metabolism • integrative genomics • GWAS • pathway and network analysis • coagulation factor II

Lipid metabolism is vital for organisms as it provides energy as well as essential materials such as membrane components and signaling molecules for basic cellular functions. Lipid dysregulation is closely related to many complex human diseases, such as atherosclerotic cardiovascular disease (CVD) (1), Alzheimer's disease (2, 3), type 2 diabetes (T2D) (4), and cancers (5). The notion of targeting lipid metabolism to treat human diseases has been reinforced by the fact that many disease-associated genes and drug targets (e.g., *HMGCR* as the target of statins and *PPARA* as the target of fibrates) are involved in lipid metabolic pathways (6–8).

Accumulating evidence supports that plasma lipids are complex phenotypes influenced by both environmental and genetic factors (9, 10). Heritability estimates for main plasma lipids are high [e.g., ~70% for low density lipoprotein cholesterol (LDL) and ~55% for high density lipoprotein cholesterol (HDL)] (11), indicating that DNA sequence variation plays an important role in explaining the interindividual variability in plasma lipid levels. Indeed, genome-wide association studies (GWASs) have pinpointed a total of 386 genetic loci, captured in the form of single nucleotide polymorphisms (SNPs) associated with lipid phenotypes (12–16). For example, the most recent GWAS on lipid levels identified 118 loci that had not previously been associated with lipid levels in humans, revealing a daunting genetic complexity of blood lipid traits (16).

However, there are several critical issues that cannot be easily addressed by traditional GWAS analysis. First, even very large GWAS may lack statistical power to identify SNPs with small effect sizes and as a result the most significant loci only explain a limited proportion of the genetic heritability, for example, 17.2–27.1% for lipid traits (17). Second, the functional consequences of the genetic variants and the causal genes underlying

This article contains supplemental data.

*These authors contributed equally to this work.

*For correspondence: Yuqi Zhao, zhaoyuqi616@gmail.com; Xia Yang, xyang123@ucla.edu.

Fig. 1. Overall design of the study. The statistical framework can be divided into four main parts, including Marker Set Enrichment Analysis (MSEA), merging and trimming of gene sets, Key Driver Analysis (KDA), and validation of the key drivers (KD) using in vitro testing.

the significant genetic loci are often unclear and await elucidation. To facilitate functional characterization of the genetic variants, genetics of gene expression studies (18, 19) and the ENCODE efforts (20) have documented tissue- or cell-specific expression quantitative trait loci (eQTLs) and functional elements of the human genome. These studies provide the much-needed bridge between genetic polymorphisms and their potential molecular targets. Third, the molecular mechanisms that transmit the genetic perturbations to complex traits or diseases, that is, the cascades of molecular events through which numerous genetic loci exert their effects on a given phenotype, remain elusive. Biological pathways that capture functionally related genes involved in molecular signaling cascades and metabolic reactions and gene regulatory networks formed by regulators and their downstream genes can elucidate the functional organization of an organism and provide mechanistic insights (21). Indeed, various pathway- and network-based approaches to analyzing GWAS datasets have been developed (18, 22–24) and demonstrated to be powerful to capture both the

missing heritability and the molecular mechanisms of many human diseases or quantitative phenotypes (18, 23, 25, 26). For these reasons, integrating genetic signals of blood lipids with multitissue multiomics datasets that carry important functional information may provide a better understanding of the molecular mechanisms responsible for lipid regulation as well as the associated human diseases.

In this study, we apply an integrative genomics framework to identify important regulatory genes, biological pathways, and gene subnetworks in relevant tissues that contribute to the regulation of four critical blood lipid traits, namely, total cholesterol (TC), HDL, LDL, and triglyceride (TG). We combine the GWAS results from the Global Lipids Genetics Consortium (GLGC) with functional genomics data from a number of tissue-specific eQTLs and the ENCODE project, and gene-gene relationship information from biological pathways and data-driven gene network studies. The integrative framework comprises four main parts (Fig. 1): 1) Marker Set Enrichment Analysis (MSEA) where GWAS, functional genome, and pathways or

coregulated genes are integrated to identify lipid-related functional units of genes, 2) merging and trimming of identified lipid gene sets, 3) key driver analysis (KDA) to pinpoint important regulatory genes by further integrating gene regulatory networks, and 4) validation of key regulators using genetic perturbation experiments and in silico evidence. This integrated systems biology approach enables us to derive a comprehensive view of the complex and novel mechanisms underlying plasma lipid metabolism.

MATERIALS AND METHODS

GWAS of lipid traits

The experimental design, genotyping, and association analyses of HDL, LDL, TC, and TG were described previously (12). The dataset used in this study comprises >100,000 individuals of European descent (sample size 100,184 for TC, 95,454 for LDL, 99,900 for HDL, and 96,598 for TG), ascertained in the United States, Europe, or Australia. More than 906,600 SNPs were genotyped using Affymetrix Genome-Wide Human SNP Array 6.0. Imputation was further carried out to obtain information for up to 2.6 million SNPs using the HapMap CEU (Utah residents with ancestry from northern and western Europe) panel. SNPs with minor allele frequency (MAF) <1% were removed. Finally, a total of ~2.6 million SNPs tested for association with each of the four lipid traits were used in our study.

Genetic association study of lipid traits using MetaboChip

The experimental design, genotyping, and association analyses of the lipid MetaboChip study were described previously (15). The study examined subjects of European ancestry, including 93,982 individuals from 37 studies genotyped with the MetaboChip array, comprising 196,710 SNPs representing candidate loci for cardiometabolic diseases. There was limited overlap between the individuals involved in GWAS and those in MetaboChip.

Knowledge-based biological pathways

We included canonical pathways from the Reactome (version 45), Biocarta, and the Kyoto Encyclopedia of Genes and Genomes (KEGG) databases (27, 28). In addition to the curated pathways, we constructed four positive control pathways based on known lipid-associated loci ($P < 5.0 \times 10^{-8}$) and candidate genes from the GWAS Catalog (29). These gene sets were based on 4, 11, 13, and 13 studies for TC, TG, LDL, and HDL, respectively (full lists of genes in each positive control sets are in [supplemental Table S1](#)), and serve as positive controls to validate our computational method.

Data-driven modules of coexpressed genes

Beside the canonical pathways, we used coexpression modules that were derived from a collection of genomics studies ([supplemental Table S2](#)) of liver, adipose tissue, human aortic endothelial cells (HAECs), brain, blood, kidney, and muscle (30–39). A total of 2,706 coexpression modules were used in this study. Although liver and adipose tissue are likely the most important tissues for lipid regulation, we included

the other tissue networks to confirm whether known tissue types for lipids could be objectively detected and whether any additional tissue types are also important for lipids.

Mapping SNPs to genes

Three different mapping methods were used in this study to link SNPs to their potential target genes.

Chromosomal distance-based mapping. First, we used a standard distance-based approach where a SNP was mapped to a gene if within 50 kb of the respective gene region. The use of ± 50 kb to define gene boundaries is commonly used in GWAS.

eQTL-based mapping. The expression levels of genes can be seen also as quantitative traits in GWAS. Hence, it is possible to determine eQTLs and the expression SNPs (eSNPs) within the eQTLs that provide a functionally motivated mapping from SNPs to genes. Moreover, the eSNPs within the eQTL are specific to the tissue where the gene expression was measured and can therefore provide mechanistic clues regarding the tissue of action when intersected with lipid-associated SNPs. Results from eQTL studies in human adipose tissue, liver, brain, blood, and HAEC were used in this study (30, 32–34, 38–45). We included both *cis*-eSNPs (within 1 Mb distance from gene region) and *trans*-eSNPs (beyond 1 Mb from gene region), at a false discovery rate (FDR) <10%.

ENCODE-based mapping. In addition to the eQTLs and distance-based SNP-gene mapping approaches, we integrated functional data sets from the Regulome database (20), which annotates SNPs in regulatory elements in the *Homo sapiens* genome based on the results from the ENCODE studies (46).

Nine unique combinations of SNP-gene mapping. Using the above three mapping approaches, we derived nine unique sets of SNP-gene mapping. These are: eSNP adipose, eSNP liver, eSNP blood, eSNP brain, eSNP HAEC, eSNP all (i.e., combining all the tissue-specific eSNPs above); Distance (chromosomal distance-based mapping); Regulome (ENCODE-based mapping); and Combined (combining all the above methods).

Removal of SNPs in linkage disequilibrium

We observed a high degree of linkage disequilibrium (LD) in the eQTL, Regulome, and distance-based SNPs, and this LD structure may cause artifacts and biases in the downstream analysis. For this reason, we devised an algorithm to remove SNPs in LD while preferentially keeping those with a strong statistical association with lipid traits. Technical details are available in [supplementary methods](#). We chose an LD cutoff ($r^2 < 0.5$) to remove redundant SNPs in high LD.

Marker Set Enrichment Analysis

We applied a modified MSEA method (24, 47) to find pathways/coexpressed modules associated with lipid traits ([supplemental methods](#)). FDRs were estimated with the method by Benjamini and Hochberg (48). Pathways or coexpression modules with a FDR < 10% were considered statistically significant. MSEA was applied to both the GLGC GWAS dataset and the MetaboChip dataset. The combined FDR from these two datasets was expected to be <1% ($10\% \times 10\% = 1\%$).

Comparison between MSEA and other computational methods

To ensure that the pathway results from MSEA are reproducible, we used the improved gene-set-enrichment analysis (iGSEA) approach (49). In the iGSEA analysis, we generated gene sets using the same canonical pathways and coexpression modules in MSEA. The SNPs were mapped to genes using the default settings of iGSEA. For each given gene set, significance proportion-based enrichment score was calculated to estimate the enrichment of genotype-phenotype association. Then, iGSEA performed label permutations to calculate nominal *P*-values to assess the significance of the pathway-based enrichment score and FDR to correct multiple testing, with a FDR < 25% (default setting) regarded as significant pathways. Considering that MSEA and iGSEA were independent, the combined FDR from these two methods of analysis was expected to be <5% ($10\% \times 25\% = 2.5\%$).

Construction of independent supersets and confirmation of lipid association

Because the pathways or coexpression modules were collected from multiple sources, there were overlapping or nested structures among the gene sets. To make the results more meaningful, we constructed relatively independent supersets that captured the core genes from groups of redundant pathways and coexpression modules (supplemental methods). After merging, we annotated each superset based on function enrichment analysis of the known pathways from the Gene Ontology and KEGG databases ($P < 0.05$ in Fisher's exact test after Bonferroni correction). The supersets were given a second round of MSEA to confirm their significance associated with lipids using $P < 0.05$ after Bonferroni correction as the cutoff.

Key driver analysis

We adopted a previously developed KDA algorithm (50–52) of gene-gene interaction networks to the lipid-associated supersets in order to identify the key regulatory genes (Fig. 1). In the study, we included Bayesian gene regulatory networks from diverse tissues, including adipose tissue, liver, blood, brain, kidney, and muscle (30–38). A key driver (KD) was defined as a gene that is directionally connected to a large number of genes from a lipid superset, compared with the expected number for a randomly selected gene within the Bayesian network (details in supplemental methods). The MSEA, merging, and KDA were performed using R.

Enrichment analysis of lipid-associated subnetworks in human complex diseases

We collected disease susceptibility genes from the GWAS Catalog with GWAS $P < 10E-5$ for four human complex diseases, including CVD [“myocardial infarction,” “myocardial infarction (early onset),” “coronary artery calcification,” and “coronary heart disease”], Alzheimer's disease, T2D, and cancer [“colon cancer,” “breast cancer,” “pancreas cancer,” “prostate cancer,” and “chronic lymphocytic leukemia”]. Fisher's exact test was used to explore the enrichment of genes in the lipid-associated subnetworks in the disease gene sets. Bonferroni-corrected $P < 0.05$ was considered significant.

Validation of *F2* in adipocyte functions via *F2* siRNA transfection in 3T3-L1 and C3H10T1/2 adipocyte cell lines

The mouse preadipocytes 3T3-L1 and C3H10T1/2 cells were obtained from ATCC and maintained and differentiated to adipocytes according to the manufacturer's instruction. For knockdown experiments, three predesigned siRNAs targeting *F2* gene (sequences in supplemental Table S3; GenePharma, Paramount, CA) were tested and the most effective one was selected for the experiment (supplemental Fig. S1). We first measured *F2* expression during adipocyte differentiation and found increased *F2* expression on days 8–10 in 3T3-L1 and days 6–10 in C3H10T1/2 during differentiation, which helped inform on the timing of siRNA transfection in these cell lines. 3T3-L1 adipocytes were transfected with 50 nM of *F2* siRNA using Lipofectamin 2000 on day 7 (D7) of differentiation, a day before *F2* increase. Followed by 72 h of siRNA treatment, adipocytes were processed for Oil red O staining of lipids and Real-time qPCR for select genes. C3H10T1/2 adipocytes were transfected with 50 nM of *F2* siRNA using Lipofectamin 2000 on day 5 (D5) and day 7 (D7), and adipocytes were processed on day 9 (D9) for Oil red O staining of lipids, real-time qPCR for select genes, and quantitative lipid assays. As control, 50 nM of scrambled siRNA (GenePharma) was transfected at the same time points as the *F2* siRNA in the two cell lines. To determine changes in lipid accumulation, adipocytes were stained by Oil red O stain solution. After obtaining images, Oil red O was eluted in isopropyl alcohol and absorbance values were measured at 490 nm.

RNA extraction and real-time qPCR

Total RNA was extracted from the adipocytes (Zymo Research, Irvine, CA), and RNA was reverse transcribed using cDNA Reverse Transcription Kit (Thermo Scientific, Madison, WI), real-time qPCR for select network and nonnetwork genes was performed using the primers shown in supplemental Table S3. Each reaction mixture (20 μ l) is composed of PowerUp SYBR Green Master Mix (Applied Biosystems), 0.5 μ M each primer, and cDNA (150 ng for *F2* gene, 20–50 ng for the other genes). Each sample was tested in duplicate under the following amplification conditions: 95°C for 2 min, and then 40 cycles of 95°C for 1 s and 60°C for 30 s in QuantStudio 3 Real-Time PCR System (Applied Biosystems, Foster City, CA). PCR primers were designed using the Primer-BLAST tool available from the NCBI web site (53). Melt curve was checked to confirm the specificity of the amplified product. Relative quantification was calculated using the $2^{-\Delta\Delta CT}$ method (54). Beta-actin was used as an endogenous control gene to evaluate the gene expression levels. All data are presented as the mean $\pm$ SEM of $n = 4$ /group. Statistical significance was determined by two-tailed Student's *t*-test and values were considered statistically significant at $P < 0.05$.

Extraction and quantification of lipids in cells and media

Lipids were extracted from C3H10T1/2 cells and culture media using the Folch method (55) with minor modifications. Briefly, whole culture medium (1 ml) from each well of a 12-well plate was collected in a separate tube. Cells were washed with phosphate buffered saline (PBS) and collected in 1 ml PBS and homogenized. The media or cell homogenate was

TABLE 1. Common pathways shared by the four lipid traits in SNP set enrichment analysis

Categories	Descriptions	Traits ^a				MetaboChip	iGSEA
		HDL	LDL	TC	TG		
Positive controls	Positive control gene set for TG	1,2,3,5,6,7,8,9	2,3,5,6,7,8,9	2,3,5,6,7,8,9	1,2,3,5,6,7,8,9	Yes	Yes
	Positive control gene set for LDL	5,6,7,8,9	1,2,3,4,5,6,7,8,9	1,2,3,4,5,6,7,8,9	1,2,3,5,6,7,8,9	Yes	Yes
	Positive control gene set for TC	3,5,6,7,8,9	1,2,3,4,5,6,7,8,9	1,2,3,4,5,6,7,8,9	1,2,3,5,6,7,8,9	Yes	Yes
	Positive control gene set for HDL	1,2,3,4,5,6,7,8,9	2,6,7,8,9	2,5,6,7,8,9	1,2,5,6,7,8,9	Yes	Yes
Lipid metabolism	Lipoprotein metabolism	1,2,5,6,7,8,9	5,6,7,8,9	5,6,7,8,9	5,6,7,8,9	Yes	Yes
	Chylomicron-mediated lipid transport	5,6,7,8,9	7,8,9	5,6,7,8,9	5,6,7,8,9	Yes	Yes
	LDL-mediated lipid transport	6,7,9	6,7,9	6,7,9	6,7,9	No	Yes
	HDL-mediated lipid transport	1,2,5,6,7,8,9	5,7,8,9	5,7,8,9	5,7,8,9	Yes	Yes
Protein catabolism	ER-phagosome pathway	1,5,8,9	1,3,5,6,8,9	1,2,3,5,6,8,9	1,3,5,6,8,9	Yes	Yes
	Antigen processing and presentation	5,9	1,2,3,5,6,7,8,9	1,2,3,5,6,7,8,9	1,2,3,5,6,7,8,9	Yes	Yes
Interferon signaling	Interferon signaling	7,9	1,3,5,6,8,9	1,2,3,5,6,8,9	1,3,5,8	Yes	Yes
Autoimmune/immune activation	Type I diabetes mellitus	1,5	1,2,3,5,6,7,8,9	1,2,3,5,6,7,8,9	1,2,3,5,6,7,8,9	Yes	Yes
	Scavenging by class B receptors	6,7,8,9	7,9	7,9	7,9	No	Yes
	Asthma	6	1,3,5,6,7,8,9	1,2,3,5,6,7,8,9	1,2,3,5,6,7,8,9	Yes	Yes
	IL 5 signaling pathway	5	1,5,6,8,9	1,5,6,8,9	5,6,8	No	No
	Th1/Th2 differentiation	3	1,3,5,6,8	1,3,5,6,8,9	1,3,5,6,8	No	Yes
	Natural killer cell-mediated cytotoxicity	5	1,3,5	1,3,5,6,9	1,3,5	Yes	Yes
	HLA genes	1,3,5,6,7,8,9	1,2,3,5,6,7,8,9	1,2,3,5,6,7,8,9	1,2,3,5,6,7,8,9	Yes	Yes
	Cell adhesion molecules (CAMs)	5	1,2,3,5,6,7,8,9	1,2,3,5,6,7,8,9	1,3,5,6,8,9	Yes	No
	Autoimmune thyroid disease	1,3,5,6,8,9	1,2,3,5,6,7,8,9	1,2,3,5,6,7,8,9	1,2,3,5,6,7,8,9	Yes	Yes
Visual transduction	Diseases associated with visual transduction	7	7,8,9	7,8,9	7,9	Yes	Yes
	Visual phototransduction	7	7,8,9	7,8,9	7,9	Yes	Yes

^aThe Traits columns represent in which methods the MSEA of the pathways is significant with FDR < 10%. Numbers 1–9 represent adipose eSNP (1), blood eSNP (2), brain eSNP (3), human aortic endothelial cells (HAEC) eSNP (4), liver eSNP (5), all eSNP (6), distance (7), regulome (8), and combined (9), respectively. The MetaboChip and iGSEA columns tell whether the gene set can also be detected as statistically significant in the analysis.

mixed in 5 ml of chloroform:methanol (2:1, vol/vol) by shaking vigorously several times and centrifuged at 2,500 *g* for 15 min. The bottom organic layer was transferred to a new glass tube. The remaining aqueous phase and interphase including the soluble protein were mixed with 5 ml chloroform by vigorous shaking, followed by centrifugation at 2,500 *g* for 15 min. The bottom organic layer was combined with the first collected organic layer. The combined organic phase was evaporated using nitrogen, and then the dried lipids were resuspended in 0.5% Triton X-100 in water. Samples were stored in –80°C until lipid analysis. TG, TC, unesterified cholesterol (UC), and phospholipid levels in lipid extractions from cells and from culture media were measured separately using a colorimetric assay at the UCLA GTM Mouse Transfer Core (56). Intracellular lipids were normalized to the cellular protein amount measured by BCA protein assay kit (Pierce, Rockford, IL). Extracellular lipids are presented as lipid quantity in 1 ml of collected media.

RESULTS

Identification of pathways and gene coexpression modules associated with lipid traits

To assess biological pathway enrichment for the four lipid traits with GLGC GWAS, we curated a total of 4,532 gene sets including 2,705 tissue-specific coexpression modules (i.e., highly coregulated genes based on tissue gene expression data) and 1,827 canonical pathways from Reactome, Biocarta and KEGG. These gene sets were constructed as data- and knowledge-driven functional units of genes. Four predefined

positive control gene sets for HDL, LDL, TC, and TG were also created based on candidate genes curated from the GWAS catalog (57). To map potential functional SNPs to genes in each gene set, tissue-specific eQTLs, ENCODE functional genomics information, and chromosomal distance-based mapping were used (details in Methods). Tissue-specific eQTL sets were obtained from the GTEx database from studies on human adipose tissue, liver, brain, blood, and HAECs, and a total of nine SNP-gene mapping methods were created. The liver and adipose tissues have established roles in lipid regulation, whereas the other tissues are included for comparison.

On integration of the datasets mentioned above using MSEA, we identified 65, 86, 90, and 92 gene sets whose functional genetic polymorphisms showed significant association with HDL, LDL, TC, and TG, respectively, in GLGC GWAS (FDR < 10%; supplemental Table S4). The predefined positive controls for the four lipid traits were among the top signals for their corresponding traits (Table 1), indicating that our MSEA method is sensitive in detecting true lipid trait-associated processes. Compared with other tissues, more pathways were captured when using liver and adipose eSNPs to map GWAS SNPs to genes (supplemental Table S4). For example, 56 of the 86 LDL-associated pathways were found when liver and adipose eSNPs were used in our analysis. These results confirmed the general notion that liver and adipose

TABLE 2. Trait-specific pathways identified in the SNP set enrichment analysis for four lipid traits

Traits	Modules	Descriptions	Methods ^a
HDL	rctm0846	Packaging of telomere ends	1
	Haec:M1 ^b	(Cholesterol biosynthesis)	9
	M12882	Taurine and hypotaurine metabolism	1,5
	rctm0060	Activation of genes by ATF4	9
	rctm0216	Cation-coupled chloride cotransporters	7,8,9
	rctm0697	Metabolism of water-soluble vitamins and cofactors	5
	Cerebellum:M1 ^b	(Alcohol metabolism)	3
	Cerebellum:M2 ^b		3
	rctm0507	Glutathione synthesis and recycling	5
	Liver:M1 ^b	(Transition metal ion homeostasis)	2,9
	rctm0937	RIG-I/MDA5-mediated induction of IFN-alpha/beta pathways	7,8,9
	rctm0772	Negative regulators of RIG-I/MDA5 signaling	7,8,9
	rctm0255	Cobalamin (Cbl, vitamin B12) transport and metabolism	1,5
	M15902	Glycerolipid metabolism	6,7,9
	rctm1178	Striated muscle contraction	9
	rctm0696	Metabolism of vitamins and cofactors	5
LDL	Haec:M2 ^b	(Positive regulation of cellular metabolism)	3
	Liver:M2 ^b	(Cadherin)	6
	Cerebellum:M3 ^b	(Immunity and defense)	8
	M6831	The citric acid cycle	6
	rctm0876	Platelet sensitization by LDL	7,9
TC	M17946	Valine, leucine, and isoleucine biosynthesis	1,6,9
	PC:M1 ^b	(Chaperone)	3
	Cerebellum:M4 ^b	(Response to wounding)	9
	Adipose:M1 ^b		8
	Omental:M1 ^b		3
TG	rctm1111	Signal transduction by L1	3
	rctm1276	Tight junction interactions	1,6,8,9
	rctm0589	Initial triggering of complement	1
	rctm0235	Cholesterol biosynthesis	2
	M18155	Insulin signaling pathway	1
	Blood:M1 ^b	(Carbohydrate metabolism)	1,6
	rctm0225	Cell-cell junction organization	1,6,8
	Blood:M3 ^b	(Transferase activity, transferring glycosyl groups)	1
	M7146	Classical complement pathway	1
	rctm0059	Activation of gene expression by SREBP (SREBF)	2
	M917	Complement pathway	1
	M5872	Steroid biosynthesis	2
	Omental:M2 ^b	(Hemopoietic or lymphoid organ development)	8
	M2164	Leukocyte transendothelial migration	1

PC, prefrontal cortex.

^aThe method column represents in which methods the MSEA of the pathways is significant with FDR < 10%. Numbers 1–9 represent: adipose eSNP (1), blood eSNP (2), brain eSNP (3), human aortic endothelial cells (HAEC) eSNP (4), liver eSNP (5), all eSNP (6), distance (7), regulome (8), and combined (9), respectively.

^bCoexpression modules. The statistically overrepresented Gene Ontologies satisfying $P < 0.01$ in Fisher's exact test after Benjamini-Hochberg correction within the modules are listed in the parentheses.

tissue play critical roles in regulating plasma lipids, leading us to focus the bulk of our analysis on these two tissues, with the remaining tissues serving as a supplement.

Among the significant gene sets, 39 were shared across the four lipid traits. These gene sets represented the expected lipid metabolic pathways as well as those that are less known to be associated with lipids, such as “antigen processing and presentation,” “cell adhesion molecules,” “visual phototransduction,” and “IL-5 signaling pathway” (summary in Table 1; details in supplemental Table S4). We broadly classified the common gene sets detected into “positive controls,” “lipid metabolism,” “interferon signaling,” “autoimmune/immune activation,” “visual transduction,” and “protein catabolism” (Table 1).

Beside the common gene sets described above, we also detected 18, 5, 6, and 17 trait-specific pathways/modules for HDL, LDL, TC, and TG, respectively (Table 2;

supplement Table S4), suggesting trait-specific regulatory mechanisms. Among the 18 pathways for HDL were “cation-coupled chloride transporters,” “glycerolipid metabolism,” and “negative regulators of RIG-I/MDA5 signaling” across analyses using different tissue eSNP mapping methods; “alcohol metabolism” from brain-based analysis; “packaging of telomere ends” in adipose tissue; “glutathione metabolism” in liver; and “cobalamin metabolism” and “taurine and hypotaurine metabolism” in both adipose and liver-based analyses. LDL-specific pathways included the “platelet sensitization by LDL” pathway and a liver coexpression module related to cadherin. TC-specific pathways included “valine, leucine, and isoleucine biosynthesis” across tissues and “wound healing” in the brain-based analysis. When looking at the TG-specific pathways, gene sets associated with “cellular junctions” were consistent across tissues, whereas “insulin signaling” and complement pathways were exclusively seen in adipose tissue-based analysis.

TABLE 3. Supersets shared by four lipid traits and key driver genes

Supersets	No. of Genes	Methods ^a				Top Adipose KDs	Top Liver KDs
		HDL	LDL	TC	TG		
Lipid metabolism	793	1,2,3,5	1,2,3,5	1,2,3,5	1,2,3,5	<i>APOH, ABCB11, F2, ALB, APOA5, APOC4, DMGDH, SERPINC1, APOF, HADHB, ETVFDH, KLKB1</i>	<i>HMGCS1, FDFT1, FADS1, DHCR7, ACAT2, ACSS2</i>
Protein catabolism	253	1,3,4,5,6,7,8,9	1,3,5,6	1,3,5,6,9	1,3,5,6,8	<i>PSMB9</i>	<i>PSMB9</i>
Interferon signaling	171	1,3,5,7,8,9	1,2,3,5,6,7,8,9	1,2,3,5,6,7,8,9	1,2,3,5,6,8,9	<i>NUP210</i>	<i>MX1, ISG15, MX2, IFI44, EPSTI1</i>
Autoimmune/immune activation	152	1,3,4,5,6,7,8,9	1,2,3,4,5,6,7,8,9	1,2,3,4,5,6,7,8,9	1,2,3,4,5,6,7,8,9	<i>HLA-DMB, HCK, SYK, CD86</i>	<i>HLA-DMB, CCL5, HLA-DQA1</i>
Visual transduction	86	7,9	7,8,9	7,8,9	7,8,9	-	-

^aThe method column represents in which methods the MSEA of the pathways is significant with Bonferroni-adjusted $P < 0.05$. Numbers 1–9 represent: adipose eSNP (1), blood eSNP (2), brain eSNP (3), human aortic endothelial cells (HAEC) eSNP (4), liver eSNP (5), all eSNP (6), distance (7), regulome (8), and combined (9), respectively.

Replication of lipid-associated pathways using additional dataset and method

To replicate our results from the analysis of GLGC GWAS datasets, we utilized an additional lipid genetic association dataset based on a MetaboChip lipid association study (15), which involved individuals independent of those included in GLGC. The gene sets detected using this independent dataset highly overlapped with those from the GLGC dataset (Table 1; supplemental Fig. S2; overlapping P values $< 10^{-20}$ by Fisher's exact test). We also utilized a different pathway analysis method iGSEA (49) and again many of the gene sets were found to be reproducible (Table 1; supplemental Fig. S2; overlapping P values $< 10^{-20}$).

Construction of nonoverlapping gene supersets for lipid traits

As the knowledge-based pathways and data-driven coexpression modules used in our analysis can converge on similar functional gene units, some of the lipid-associated gene sets have redundancies. We therefore merged overlapping pathways to derive independent, nonoverlapping gene sets-associated lipid traits. For the 39 shared pathways/coexpression modules across the four lipid traits described earlier, we merged and functionally categorized them into five independent supersets (Table 1; Table 3). For the significant gene sets for each lipid trait, we merged them into 17, 16, 18, and 14 supersets for HDL, LDL, TC, and TG, respectively (Table 3; supplemental Table S5), and confirmed that the merged supersets still showed significant association with the corresponding lipid traits in a second round of MSEA ($P < 0.05$ after Bonferroni correction for the number of supersets tested; Table 3).

Identification of central regulatory genes in the lipid-associated supersets

Subsequently, we performed a KDA (Fig. 1) to identify potential regulatory genes or KDs that may regulate genes associated with each lipid trait using Bayesian networks constructed from genetic and gene

expression datasets of multiple tissues (detailed in Methods; full KD list in supplemental Table S6). The top adipose and liver KDs for the shared supersets of all four lipid traits and the representative Bayesian subnetworks are shown in Fig. 2.

In adipose tissue (Fig. 2A), the top KDs for the “lipid metabolism” subnetwork include well-known lipoproteins and ATP-binding cassette (ABC) family members that are responsible for lipid transport, such as *APOF*, *APOA5*, and *ABCB11*. We also found several KDs that are less known to be associated with lipid metabolism, particularly *F2* (coagulation factor II or thrombin). For the autoimmune/immune activation subnetwork, *CD86*, *HCK*, and *HLA-DMB* were identified as KDs. *PSMB9* was a KD for the protein catabolism subnetwork, whereas *NUP210* is central for the interferon signaling subnetwork. Moreover, the *SYK* gene is a shared KD between lipid metabolism and autoimmune/immune activation.

In the liver (Fig. 2B), the top KDs for the lipid metabolism subnetwork are enzymes involved in lipid and cholesterol biosynthesis and metabolism, such as *FADS1* (fatty acid desaturase 1), *FDFT1* (farnesyl-diphosphate farnesyltransferase 1), *HMGCS1* (3-hydroxy-3-methylglutaryl-CoA synthase 1), and *DHCR7* (7-dehydrocholesterol reductase). We also identified more KDs for the interferon signaling subnetwork in the liver compared with the adipose tissue, with *MX1*, *MX2*, *ISG15*, *IFI44*, and *EPSTI1* being central to the subnetwork. Similar to the adipose network, *PSMB9* and *HLA-DMB* were also identified as KDs for protein catabolism and autoimmune/immune activation subnetworks in liver, respectively. We did not detect KD genes for the visual transduction subnetwork in either tissue, possibly because the networks of liver and adipose tissues did not capture gene-gene interactions important for this subnetwork.

In addition to the KDs for the subnetworks shared across lipid traits as discussed above, we identified tissue-specific KDs for individual lipid traits (supplemental Table S6). In adipose, *PANK1* and H2B histone family members were specific for the HDL

Fig. 2. Common KDs and their neighboring genes in the shared lipid-associated subnetworks. A: Adipose KDs and subnetworks. B: Liver KDs and subnetworks. The subnetworks shared by HDL, LDL, TC, and TG are depicted by different colors according to the difference in their functional categories. Nodes are the KDs and their adjacent regulatory partner genes, with KDs depicted as square nodes and their gene symbols labeled in *red letters*. Only network edges that were present in at least two independent network studies were included. The node size corresponds to the GWAS significance.

subnetworks (Fig. 3A); *HIPK2* and *FAU* were top KDs for the LDL subnetworks (Fig. 3B); genes associated with blood coagulation such as *KNG1* and *FGL1* were KDs for

the TC and TG subnetworks (Fig. 3C, D). Of interest, genes related to insulin resistance, *PPARG* and *FASN*, were KDs for both the HDL and TG subnetworks.

Fig. 3. Adipose KDs and subnetworks for each lipid trait. Panels (A)–(D) represent HDL, LDL, TC, and TG subnetworks. Nodes are the KDs and their adjacent regulatory partner genes, with KDs depicted as larger nodes. Different colors indicate genes involved in different pathways.

Similarly, trait-specific KDs and subnetworks were also detected in the liver; 37 KDs were identified for the TG subnetwork including *ALDH3B1* and *ORM2*, whereas *AHSG*, *FETUB*, *ITIH1*, *HP*, and *SERPINC1* were KDs found in the LDL subnetwork. We note that most of the KDs are themselves not necessarily GWAS hits but are surrounded by significant GWAS genes. For example, gene *F2* is centered by many GWAS hits in the adipose subnetwork (*APOA4*, *APOC3*, *APOA5*, *LIPC*, etc.; Fig. 2; supplemental Fig. S3). The observation of GWAS hits being peripheral nodes in the network is consistent with previous findings from our group and others (24, 58–62) and again supports that important regulators may not necessarily harbor common variations owing to evolutionary constraints.

Experimental validation of *F2* KD subnetworks in 3T3-L1 and C3H10T1/2 adipocytes

Taking into account that the *F2* gene is surrounded by various significant GWAS hits within its subnetwork, we aimed to validate the role of the *F2* gene subnetwork in lipid regulation through siRNA-mediated knockdown experiments in two adipocyte cell lines (3T3-L1

and C3H10T1/2) to ensure reproducibility and robustness of our results. We found that *F2* gene expression was low in preadipocytes for both cell lines but gradually increased during adipogenesis. In fully differentiated adipocytes between day 8 and day 10, the *F2* gene expression level was higher than in preadipocytes by 12-fold and sixfold for 3T3-L1 and C3H10T1/2 lines, respectively (Fig. 4A, B). When treated with *F2* siRNA, both adipocyte cell lines showed a significant decrease ($P < 0.01$) in lipid accumulation based on Oil red O staining, as compared with controls treated with scrambled siRNA (Fig. 4C, D). Subsequently, we tested the effect of *F2* gene siRNA knockdown on 10 neighbors of the *F2* gene in the adipose network (selected from Fig. 2A). With 60% knockdown efficiency of *F2* siRNA in the 3T3-L1 adipocytes, seven *F2* network neighbors (*Abcb11*, *Apoa5*, *Apof*, *Fabp1*, *Lipc*, *Gc*, and *Proc*) exhibited significant changes in expression levels (Fig. 4E). With 74% knockdown efficiency of *F2* in C3H10T1/2 adipocytes, six *F2* network neighbors (*Abcb11*, *Apoa5*, *Apof*, *Fabp1*, *Lipc*, and *Plg*) showed significant changes in expression levels (Fig. 4F). Several of these genes are involved in lipoprotein transport and

Fig. 4. Validation of *F2*s predicted subnetwork and regulatory role in adipocytes. A, B: Time course of *F2* expression during adipocyte differentiation in 3T3-L1 cells (A) and C3H10T1/2 cells (B). D-2, D0, D2, D3, D4, D6, D8, D10 indicate 2 days before initiation of differentiation, day 0, day 2, day 3, day 4, day 6, day 8, and day 10 of differentiation, respectively. Sample size $n = 2-3$ /time point. C, D: Visualization and quantification (absorbance value) of lipid accumulation by Oil red O staining in 3T3-L1 adipocytes (C) and C3H10T1/2 adipocytes (D). Sample size $n = 5-8$ /group for adipocytes. E, F: Fold change of expression level for *F2* adipose subnetwork genes and negative control genes after siRNA knockdown. At day 7 of differentiation of 3T3-L1 and day 5 and day 7 of differentiation of C3H10T1/2, adipocytes were transfected with *F2* siRNA for the knockdown experiments. Ten *F2* neighbors were randomly selected from the first- and second-level neighboring genes of *F2* in adipose network. Four negative controls were randomly selected from the genes not directly connected to *F2* in the adipose network. G, H: The fold changes of

fatty acid uptake. In contrast, none of the four negative controls (random genes not in the F2 network neighborhood) showed significant changes in their expression levels for the 3T3-L1 cell line. However, one negative control gene (*Snrpb2*) did change in the C3H10T1/2 cell line. These results overall support our computational predictions on the structures of F2 gene subnetworks.

Next, we measured the expression levels of genes related to adipogenesis (*Pparg*, *Cepba*, *Srebp1*, *Fasn*), lipolysis (*Lipe*), fatty acid transport (*Cd36*, *Fabp4*), and other adipokines following F2 siRNA treatment. We found no change in the expression of most of the tested genes, with the exception of *Fasn* (in C3H10T1/2), important in the formation of long-chain fatty acids, and *Cd36* (in both 3T3-L1 and C3H10T1/2), which encodes fatty acid translocase facilitating fatty acid uptake. *Cd36* expression was decreased by 15% in 3T3-L1 cells (Fig. 4G) and 35% in C3H10T1/2 cells (Fig. 4H) ($P < 0.05$), and *Fasn* expression was decreased by 25% (Fig. 4H) ($P < 0.01$) in C3H10T1/2 cells compared with control. The decreases in *Cd36* and *Fasn* after F2 knockdown suggest that fatty acid synthesis and uptake by adipocytes are compromised, which could contribute to alterations in circulating lipid levels.

We subsequently measured the lipid contents within the cells and in the media of C3H10T1/2 adipocytes. Following F2 siRNA treatment, we found significant decreases in the total intracellular lipid levels (cTotal Lipid), total cholesterol (cTC), and unesterified cholesterol (cUC), as well as a nonsignificant trend for decreased triglycerides (cTG) (Fig. 4I). By contrast, in the culture media, there were significant increases in the total lipid levels (mTotal Lipid) and triglycerides (mTG) following F2 siRNA treatment (Fig. 4J). These results support that F2 knockdown led to decreased intracellular lipids and increased extracellular lipids, agreeing with the overall decreased expression of F2 network neighbor genes involved in lipid transport and uptake.

The association between the lipid subnetworks and human diseases

Epidemiological studies consistently show that plasma lipids are closely associated with human complex diseases. For example, high TC and LDL levels are associated with an increased risk of CVD. Here, we examined the association between the lipid subnetworks identified in our study and four human complex diseases, namely, Alzheimer's disease, CVD,

T2D, and cancer (Materials and Methods). We found that the gene supersets identified for each lipid traits were significantly enriched for GWAS candidate genes reported by GWAS catalog for the four diseases at Bonferroni-corrected $P < 0.05$ (Fig. 5; supplemental Table S7). The superset lipid metabolism, which was shared across lipid traits, was associated with Alzheimer's disease and CVD. When trait-specific subnetworks were considered, those associated with TC, LDL, and TG had more supersets associated with CVD compared with those associated with HDL, a finding consistent with recent reports (15, 63, 64). In addition, supersets of each lipid trait, except HDL, were also found to be significantly associated with cancer, whereas supersets associated with HDL, LDL, and TG, but not TC, were linked to T2D.

DISCUSSION

To gain comprehensive insights into the molecular mechanisms of lipid traits that are important for numerous common complex diseases, we leveraged the large volume of genomic datasets and performed a data-driven multiomics study combining genetic association signals from large lipid GWASs, tissue-specific eQTLs, ENCODE functional data, known biological pathways, and gene regulatory networks. We identified diverse sets of biological processes, guided by their tissue-specific gene-gene interactions, to be associated with individual lipid traits or shared across lipid traits. Many of the lipid-associated gene sets were significantly linked to multiple complex diseases including CVD, T2D, cancer, and Alzheimer's disease. More importantly, we elucidated tissue-specific gene-gene interactions among the gene sets and identified both well-characterized and novel KDs for these lipid-associated processes. We further experimentally validated a novel adipose lipid regulator, F2, in two different adipocyte cell lines. Our results offer new insight into the molecular regulation of lipid metabolism, which would not have been possible without the systematic integration of diverse genetic and genomic datasets.

We identified shared pathways associated with all four lipid traits, including lipid metabolism and autoimmune/immune activation, which have been consistently linked to lipid phenotypes, as well as additional pathways such as interferon signaling, protein catabolism, and visual transduction. Interferon factors have previously been linked to lipid storage attenuation and

adipokine/adipogenesis-related genes in 3T3-L1 (G) and in C3H10T1/2 (H). Gene expression levels were determined by RT-qPCR, normalized to beta-actin. The fold changes were relative to scrambled siRNA control. Sample size $n = 4/\text{group}$. I, J: Lipid profiles: total lipid, triglyceride (TG), total cholesterol (TC), unesterified cholesterol (UC), and phospholipid (PL) in C3H10T1/2 cells (I) and in media (J). Total Lipid was estimated using the sum of the four lipids (TG, TC, UC, PL). Intracellular lipids plotted in (I) were normalized to total cellular protein quantity. Extracellular lipids plotted in (J) are presented as lipid quantity in 1 ml of collected media. Sample size $n = 6/\text{group}$. Results represent mean $\pm$ SEM. Statistical significance was determined by two-sided Student's t -test (* $P < 0.05$ and ** $P < 0.01$).

Fig. 5. The associations between lipid-associated supersets and human complex diseases. The edges represent the associations between supersets for the specific lipid classes matched by color and diseases (P value < 0.05; Fisher exact test with Bonferroni correction). AD, Alzheimer's disease; CVD, cardiovascular diseases; T2D, type 2 diabetes.

differentiation in human adipocytes (65). Protein catabolism has only recently been identified to be important in regulating lipid metabolism through the PSMD9 protein, which had no previously known function but was shown to cause significant alterations in lipid abundance in both a gain of function and loss of function study in mice (66). The visual transduction superset contains retinol-binding proteins, which are carrier proteins involved retinol transport, and play key roles in gene expression regulation and developmental processes (67). Visual transduction also shares lipoprotein genes with lipid metabolism, suggesting that retinol-related signal transduction is intimately linked to lipoprotein transport and hence plasma lipid levels.

Furthermore, our results indicate that the trait-specific supersets are tissue specific. For example, most TG-specific pathways were found to be significant when adipose eSNPs were used, and complement and insulin signaling pathways in the adipose tissue were specific for TG. This is in line with adipose tissue functioning as the major storage site for TG and the regulatory role of immune system and insulin signaling in adipocyte functions and fat storage (68). We also found five HDL-specific pathways, most of which are associated with glucose, lipid, and amino acid metabolism and were signals derived from liver eSNPs. As HDL acts as the major vehicle for transporting cholesterol to the liver for excretion and catabolism, the critical role of the liver as well as the connections between major metabolic pathways in HDL regulation is recapitulated by our analysis. Of interest, the TC-specific pathways can be found only when brain eSNPs are used. The brain accounts for 2% of body

weight, whereas it contains 23% of TC in the body (69), and dysregulated cholesterol trafficking appears to be involved in the pathogenesis of neurodegenerative diseases, such as Parkinson's and Alzheimer's disease (70). These tissue- and trait-specific pathways or processes support the unique features of each lipid species and point to tissue-specific targeting strategies to modulate levels of individual lipid traits and the associated diseases.

In addition to detecting trait- and tissue-specific causal pathways for the lipid traits, our study attempted to delineate the interactions between lipid genes and pathways through gene network analysis. Indeed, the tissue-specific gene networks revealed in our study highlight the regulatory connections between lipid genes and pathways and thus put individual genes in a broader context. The identification of KDs in a network is essential for uncovering key regulatory components and for identifying drug targets and biomarkers for complex diseases (24, 71). Here, we adopted data-driven Bayesian gene regulatory networks that combine various genomic data (50) to detect the central genes in plasma lipid regulation. The power of this data-driven objective approach has been demonstrated recently (24, 51, 60, 61, 72, 73) and is again supported in this study by the fact that many KDs detected are known regulators for lipids or have served as effective drug targets based on the DrugBank database (74). For instance, for the shared lipid metabolism subnetwork, four top KDs (*ACAT2*, *ACSS2*, *DHCR7*, and *FADS1*) are targeted by at least one US Food and Drug Administration-approved anticholesteremic drug. Another KD, *HMGCS1*, is a rate-limiting enzyme of

cholesterol synthesis, and is considered a promising drug target in lipid-associated metabolic disorders (75). These lines of evidence lead us to speculate that the other less-studied KDs are also important for lipid regulation.

Among the top network KDs predicted, several, including *F2*, *KLKB1*, and *ANXA4*, are involved in blood coagulation. A previous study revealed that polymorphisms in the anticoagulation genes modify the efficacy of statins in reducing the risk of cardiovascular events (76), which in itself is not surprising. However, the intimate relationship between a coagulation gene *F2* and lipid regulation predicted by our analysis is intriguing (Fig. 4). We found that the partner genes in the adipose *F2* subnetwork tend to be differentially expressed after *F2* knockdown in both 3T3-L1 and C3H10T1/2 adipocytes, with several of the altered genes (*Apoa5*, *ApoJ*, *Abcb11*, *Fabp1*, *Fasn*, and *Cd36*) closely associated with cholesterol and fatty acid transport and uptake. We further observed that *F2* knockdown affects lipid storage in adipocytes, with a decrease in the intracellular lipid content and an increase in the extracellular lipid content in the media. Of interest, the *F2* expression level is low in preadipocytes and only increases during the late phase of adipocyte differentiation. Our findings support a largely untapped role of *F2* in lipid transport and storage in adipocytes and provide a novel target in the *F2* gene.

In addition to the shared KDs such as *F2* for different lipids, it may also be of value to focus on the trait-specific KDs as numerous studies have revealed that these lipid phenotypes play different roles in many human diseases. For example, LDL and TC are important risk factors for CVD (77) and TG has been linked to T2D (78), whereas the role of HDL in CVD has been controversial (79). We detected 37 genes as TG-specific KDs in liver regulatory subnetworks. Among these, *CP* (ceruloplasmin) and *ALDH3B1* (aldehyde dehydrogenase 3 family, member B1) were clinically confirmed to be associated with T2D (80, 81) whereas most of the other genes such as *DHODH* and *ANXA4* were less known to be associated with TG and thus may serve as novel targets. In adipose tissue, genes important for insulin resistance and diabetes such as *PPARG* and *FASN* were found to be KDs for TG, further supporting the connection between TG and diabetes. In addition, *FASN* has been implicated as a KD in numerous studies for nonalcoholic fatty liver disease (62, 73, 82), again highlighting the importance of this gene in common metabolic disorders.

We acknowledge some potential limitations to our study. First, the GWAS datasets utilized are not the most recently conducted and therefore provide the possibility of not capturing the full array of unknown biology. However, despite this, our results are consistent with the biology found more recently including overlapping signals in pathways for chylomicron-mediated lipid transport and lipoprotein metabolism (83) as well as more novel findings such as visual transduction

pathways. In addition, one of our KDs *KLKB1*, which was not found to be a GWAS hit in the dataset we utilized, has since been found to pass the genome-wide significance threshold in more recent larger GWASs and is a hit on apolipoprotein A-IV concentrations, which is a major component of HDL and chylomicron particles important in reverse cholesterol transport (84). This further exemplifies the robustness of our integrative network approach to find key genes important to disease pathogenesis even when smaller GWASs were utilized.

In summary, we used an integrative genomics framework to leverage a multitude of genetic and genomic datasets from human studies to unravel the underlying regulatory processes involved in lipid phenotypes. We not only detected shared processes and gene regulatory networks among different lipid traits but also provide comprehensive insight into trait-specific pathways and networks. The results suggest there are both shared and distinct mechanisms underlying very closely related lipid phenotypes. The tissue-specific networks and KDs identified in our study shed light on the molecular mechanisms involved in lipid homeostasis. If validated in additional population genetic and mechanistic studies, these molecular processes and genes can be used as novel targets for the treatment of lipid-associated disorders such as CVD, T2D, Alzheimer's disease, and cancers.

Data availability

All genomic data utilized in the analysis were previously published and were downloaded from public data repositories. All experimental data were presented in the current manuscript. Mergeomics code is available at R Bioconductor <https://doi.org/10.18129/B9.bioc.Mergeomics>.

Acknowledgments

We would like to thank Dr Aldons J. Lusis in the Department of Human Genetics, UCLA for valuable discussions during the preparation of the manuscript. We would also like to thank Gajalakshmi Ramanathan for technical support with the in vitro validation analysis and Dr Marcus Tol and Dr Peter Tontonoz in the Department of Pathology and Laboratory Medicine in the David Geffen School of Medicine at UCLA for providing the C3H10T1/2 adipocyte cell lines.

Author contributions

X. Y. and Y. Z. designed and directed the study. M. B., Y. Z., I. S. A., Z. S., and H. L. conducted the analyses. V.-P. M. contributed analytical methods and tools. M. B., Z. S., I. S. A., Y. Z., and X. Y. wrote the manuscript. I. S. A. and I. C. conducted the validation experiments. All authors edited and approved the final manuscript.

Author ORCIDs

Montgomery Blencowe <https://orcid.org/0000-0001-7147-1895>

Funding and additional information

X. Y. is supported by the National Institutes of Health Grants R01 DK104363 and R01 DK117850. The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Institutes of Health.

Conflict of interest

The authors declare that they have no conflicts of interest with the contents of this article.

Abbreviations

CVD, cardiovascular disease; eQTL, expression quantitative trait locus; eSNP, expression SNP; FDR, false discovery rate; GLGC, Global Lipids Genetics Consortium; GWAS, genome-wide association study; HAEC, human aortic endothelial cell; iGSEA, improved gene-set-enrichment analysis; KDA, key driver analysis; KEGG, Kyoto Encyclopedia of Genes and Genomes; LD, linkage disequilibrium; MAF, minor allele frequency; MSEA, Marker Set Enrichment Analysis; T2D, type 2 diabetes; TC, total cholesterol; TG, triglyceride; UC, unesterified cholesterol.

Manuscript received February 28, 2020, and in revised form December 4, 2020. Published, JLR Papers in Press, December 23, 2020, <https://doi.org/10.1194/jlr.RA120000713>

REFERENCES

- Austin, M. A. (1991) Plasma triglyceride and coronary heart-disease. *Arterioscler. Thromb.* **11**, 2–14
- Reitz, C., Tang, M. X., Luchsinger, J., and Mayeux, R. (2004) Relation of plasma lipids to Alzheimer disease and vascular dementia. *Arch. Neurol.* **61**, 705–714
- Di Paolo, G., and Kim, T. W. (2011) Linking lipids to Alzheimer's disease: cholesterol and beyond. *Nat. Rev. Neurosci.* **12**, 284–296
- Muoio, D. M., and Newgard, C. B. (2008) Molecular and metabolic mechanisms of insulin resistance and β -cell failure in type 2 diabetes. *Nat. Rev. Mol. Cell Biol.* **9**, 193
- Zhang, F., and Du, G. (2012) Dysregulated lipid metabolism in cancer. *World J. Biol. Chem.* **3**, 167
- Zhang, B. B., Zhou, G. C., and Li, C. (2009) AMPK: an emerging drug target for diabetes and the metabolic syndrome. *Cell Metab.* **9**, 407–416
- Libby, P., Ridker, P. M., and Hansson, G. K. (2011) Progress and challenges in translating the biology of atherosclerosis. *Nature* **473**, 317–325
- Tabas, I., and Glass, C. K. (2013) Anti-inflammatory therapy in chronic disease: challenges and opportunities. *Science* **339**, 166–172
- Heller, D. A., Defaire, U., Pedersen, N. L., Dahlen, G., and McClearn, G. E. (1993) Genetic and environmental influences on serum-lipid levels in twins. *N. Engl. J. Med.* **328**, 1150–1156
- Kathiresan, S., Melander, O., Guiducci, C., Surti, A., Burt, N. P., Rieder, M. J., Cooper, G. M., Roos, C., Voight, B. F., Havulinna, A. S., Wahlstrand, B., Hedner, T., Corella, D., Tai, E. S., Ordovas, J. M., et al. (2008) Six new loci associated with blood low-density lipoprotein cholesterol, high-density lipoprotein cholesterol or triglycerides in humans. *Nat. Genet.* **40**, 189–197
- van Dongen, J., Willemsen, G., Chen, W. M., de Geus, E. J., and Boomsma, D. I. (2013) Heritability of metabolic syndrome traits in a large population-based sample. *J. Lipid Res.* **54**, 2914–2923
- Teslovich, T. M., Musunuru, K., Smith, A. V., Edmondson, A. C., Stylianou, I. M., Koseki, M., Pirruccello, J. P., Ripatti, S., Chasman, D. I., Willer, C. J., Johansen, C. T., Fouchier, S. W., Isaacs, A., Peloso, G. M., Barbalic, M., et al. (2010) Biological, clinical and population relevance of 95 loci for blood lipids. *Nature* **466**, 707–713
- Kathiresan, S., Manning, A. K., Demissie, S., D'Agostino, R. B., Surti, A., Guiducci, C., Gianniny, L., Burt, N. P., Melander, O., Orho-Melander, M., Arnett, D. K., Peloso, G. M., Ordovas, J. M., and Cupples, L. A. (2007) A genome-wide association study for blood lipid phenotypes in the Framingham Heart Study. *BMC Med. Genet.* **8** Suppl 1, S17
- Willer, C. J., Sanna, S., Jackson, A. U., Scuteri, A., Bonnycastle, L. L., Clarke, R., Heath, S. C., Timpson, N. J., Najjar, S. S., Stringham, H. M., Strait, J., Duren, W. L., Maschio, A., Busonero, F., Mulas, A., et al. (2008) Newly identified loci that influence lipid concentrations and risk of coronary artery disease. *Nat. Genet.* **40**, 161–169
- Willer, C. J., Schmidt, E. M., Sengupta, S., Peloso, G. M., Gustafsson, S., Kanoni, S., Ganna, A., Chen, J., Buchkovich, M. L., Mora, S., Beckmann, J. S., Bragg-Gresham, J. L., Chang, H. Y., Demirkan, A., Den Hertog, H. M., et al. (2013) Discovery and refinement of loci associated with lipid levels. *Nat. Genet.* **45**, 1274–1283
- Klarin, D., Damrauer, S. M., Cho, K., Sun, Y. V., Teslovich, T. M., Honerlaw, J., Gagnon, D. R., DuVall, S. L., Li, J., and Peloso, G. M. (2018) Genetics of blood lipids among ~ 300,000 multi-ethnic participants of the Million Veteran Program. *Nat. Genet.* **50**, 1514
- Hoffmann, T. J., Theusch, E., Haldar, T., Ranatunga, D. K., Jorgenson, E., Medina, M. W., Kvale, M. N., Kwok, P.-Y., Schaefer, C., and Krauss, R. M. (2018) A large electronic-health-record-based genome-wide study of serum lipids. *Nat. Genet.* **50**, 401
- Zhong, H., Yang, X., Kaplan, L. M., Molony, C., and Schadt, E. E. (2010) Integrating Pathway Analysis and Genetics of Gene Expression for Genome-wide Association Studies. *Am. J. Hum. Genet.* **86**, 581–591
- Lonsdale, J., Thomas, J., Salvatore, M., Phillips, R., Lo, E., Shad, S., Hasz, R., Walters, G., Garcia, F., and Young, N. (2013) The genotype-tissue expression (GTEx) project. *Nat. Genet.* **45**, 580
- Boyle, A. P., Hong, E. L., Hariharan, M., Cheng, Y., Schaub, M. A., Kasowski, M., Karczewski, K. J., Park, J., Hitz, B. C., Weng, S., Cherry, J. M., and Snyder, M. (2012) Annotation of functional variation in personal genomes using RegulomeDB. *Genome Res.* **22**, 1790–1797
- MacNeil, L. T., and Walhout, A. J. M. (2011) Gene regulatory networks and the role of robustness and stochasticity in the control of gene expression. *Genome Res.* **21**, 645–657
- Wang, K., Li, M. Y., and Bucan, M. (2007) Pathway-based approaches for analysis of genomewide association studies. *Am. J. Hum. Genet.* **81**, 1278–1283
- Zhong, H., Beaulaurier, J., Lum, P. Y., Molony, C., Yang, X., MacNeil, D. J., Weingarh, D. T., Zhang, B., Greenawalt, D., Dobrin, R., Hao, K., Woo, S., Fabre-Suver, C., Qian, S., Tota, M. R., et al. (2010) Liver and adipose expression associated SNPs are enriched for association to type 2 diabetes. *PLoS Genet.* **6**, e1000932
- Makinen, V. P., Civelek, M., Meng, Q., Zhang, B., Zhu, J., Levian, C., Huan, T., Segre, A. V., Ghosh, S., Vivar, J., Nikpay, M., Stewart, A. F., Nelson, C. P., Willenborg, C., Erdmann, J., et al. (2014) Integrative genomics reveals novel molecular pathways and gene networks for coronary artery disease. *PLoS Genet.* **10**, e1004502
- Baranzini, S. E., Galwey, N. W., Wang, J., Khankhanian, P., Lindberg, R., Pelletier, D., Wu, W., Uitdehaag, B. M. J., Kappos, L., Polman, C. H., Matthews, P. M., Hauser, S. L., Gibson, R. A., Oksenberg, J. R., Barnes, M. R., et al. (2009) Pathway and network-based analysis of genome-wide association studies in multiple sclerosis. *Hum. Mol. Genet.* **18**, 2078–2090
- Jia, P. L., Wang, L. L., Meltzer, H. Y., and Zhao, Z. M. (2010) Common variants conferring risk of schizophrenia: a pathway analysis of GWAS data. *Schizophr. Res.* **122**, 38–42
- Joshi-Tope, G., Gillespie, M., Vastrik, I., D'Eustachio, P., Schmidt, E., de Bono, B., Jassal, B., Gopinath, G. R., Wu, G. R., Matthews, L., Lewis, S., Birney, E., and Stein, L. (2005) Reactome: a knowledgebase of biological pathways. *Nucleic Acids Res.* **33**, D428–D432
- Ogata, H., Goto, S., Sato, K., Fujibuchi, W., Bono, H., and Kanehisa, M. (1999) KEGG: Kyoto Encyclopedia of Genes and Genomes. *Nucleic Acids Res.* **27**, 29–34
- Hindorff, L. A., Sethupathy, P., Junkins, H. A., Ramos, E. M., Mehta, J. P., Collins, F. S., and Manolio, T. A. (2009) Potential

- etiologic and functional implications of genome-wide association loci for human diseases and traits. *Proc. Natl. Acad. Sci. U. S. A.* **106**, 9362–9367
30. Emilsson, V., Thorleifsson, G., Zhang, B., Leonardson, A. S., Zink, F., Zhu, J., Carlson, S., Helgason, A., Walters, G. B., Gunnarsdottir, S., Mouy, M., Steinthorsdottir, V., Eiriksdottir, G. H., Bjornsdottir, G., Reynisdottir, I., *et al.* (2008) Genetics of gene expression and its effect on disease. *Nature* **452**, 423–428
 31. Derry, J. M. J., Zhong, H., Molony, C., MacNeil, D., Guhathakurta, D., Zhang, B., Mudgett, J., Small, K., El Fertak, L., Guimond, A., Selloum, M., Zhao, W. Q., Champy, M. F., Monassier, L., Vogt, T., *et al.* (2010) Identification of genes and networks driving cardiovascular and metabolic phenotypes in a mouse F2 intercross. *PLoS One* **5**
 32. Schadt, E. E., Molony, C., Chudin, E., Hao, K., Yang, X., Lum, P. Y., Kasarskis, A., Zhang, B., Wang, S., Suver, C., Zhu, J., Millstein, J., Sieberts, S., Lamb, J., GuhaThakurta, D., *et al.* (2008) Mapping the genetic architecture of gene expression in human liver. *PLoS Biol.* **6**, 1020–1032
 33. Greenawalt, D. M., Dobrin, R., Chudin, E., Hatoum, I. J., Suver, C., Beaulaurier, J., Zhang, B., Castro, V., Zhu, J., Sieberts, S. K., Wang, S., Molony, C., Heymsfield, S. B., Kemp, D. M., Reitman, M. L., *et al.* (2011) A survey of the genetics of stomach, liver, and adipose gene expression from a morbidly obese cohort. *Genome Res.* **21**, 1008–1016
 34. Fehrmann, R. S. N., Jansen, R. C., Veldink, J. H., Westra, H. J., Arends, D., Bonder, M. J., Fu, J. Y., Deelen, P., Groen, H. J. M., Smolonska, A., Weersma, R. K., Hofstra, R. M. W., Buurman, W. A., Rensen, S., Wolfs, M. G. M., *et al.* (2011) Trans-eQTLs reveal that independent genetic variants associated with a complex phenotype converge on intermediate genes, with a major role for the HLA. *PLoS Genet.* **7**, e1002197
 35. Wang, S. S., Schadt, E. E., Wang, H., Wang, X. P., Ingram-Drake, L., Shi, W., Drake, T. A., and Lusis, A. J. (2007) Identification of pathways for atherosclerosis in mice - Integration of quantitative trait locus analysis and global gene expression data. *Circ. Res.* **101**, E11–E30
 36. Yang, X., Schadt, E. E., Wang, S., Wang, H., Arnold, A. P., Ingram-Drake, L., Drake, T. A., and Lusis, A. J. (2006) Tissue-specific expression and regulation of sexually dimorphic genes in mice. *Genome Res.* **16**, 995–1004
 37. Tu, Z. D., Keller, M. P., Zhang, C. S., Rabaglia, M. E., Greenawalt, D. M., Yang, X., Wang, J. M., Dai, H. Y., Bruss, M. D., Lum, P. Y., Zhou, Y. P., Kemp, D. M., Kendzierski, C., Yandell, B. S., Attie, A. D., *et al.* (2012) Integrative analysis of a cross-loci regulation network identifies app as a gene regulating insulin secretion from pancreatic islets. *PLoS Genet.* **8**, e1003107
 38. Nica, A. C., Parts, L., Glass, D., Nisbet, J., Barrett, A., Sekowska, M., Travers, M., Potter, S., Grundberg, E., Small, K., Hedman, A. K., Bataille, V., Bell, J. T., Surdulescu, G., Dimas, A. S., *et al.* (2011) The architecture of gene regulatory variation across multiple human tissues: the MuTHER study. *PLoS Genet.* **7**, e1002003
 39. Romanoski, C. E., Che, N., Yin, F., Mai, N., Pouladar, D., Civelek, M., Pan, C., Lee, S., Vakili, L., Yang, W. P., Kayne, P., Mungrue, I. N., Araujo, J. A., Berliner, J. A., and Lusis, A. J. (2011) Network for activation of human endothelial cells by oxidized phospholipids: a critical role of heme oxygenase 1. *Circ. Res.* **109**, E27–E41
 40. Dixon, A. L., Liang, L., Moffatt, M. F., Chen, W., Heath, S., Wong, K. C., Taylor, J., Burnett, E., Gut, I., Farrall, M., Lathrop, G. M., Abecasis, G. R., and Cookson, W. O. (2007) A genome-wide association study of global gene expression. *Nature genetics.* **39**, 1202–1207
 41. Nica, A. C., Parts, L., Glass, D., Nisbet, J., Barrett, A., Sekowska, M., Travers, M., Potter, S., Grundberg, E., Small, K., Hedman, A. K., Bataille, V., Tzenova Bell, J., Surdulescu, G., Dimas, A. S., *et al.* (2010) Transcriptome genetics using second generation sequencing in a Caucasian population. *Nature* **464**, 773–777
 42. Stranger, B. E., Montgomery, S. B., Dimas, A. S., Parts, L., Stegle, O., Ingle, C. E., Sekowska, M., Smith, G. D., Evans, D., Gutierrez-Arcelus, M., Price, A., Raj, T., Nisbett, J., Nica, A. C., Beazley, C., *et al.* (2012) Patterns of Cis regulatory variation in diverse human populations. *PLoS Genet.* **8**, 272–284
 43. Stranger, B. E., Nica, A. C., Forrest, M. S., Dimas, A., Bird, C. P., Beazley, C., Ingle, C. E., Dunning, M., Flicek, P., Koller, D., Montgomery, S., Tavare, S., Deloukas, P., and Dermitzakis, E. T. (2007) Population genomics of human gene expression. *Nat. Genet.* **39**, 1217–1224
 44. Dimas, A. S., Deutsch, S., Stranger, B. E., Montgomery, S. B., Borel, C., Attar-Cohen, H., Ingle, C., Beazley, C., Arcelus, M. G., Sekowska, M., Gagnebin, M., Nisbett, J., Deloukas, P., Dermitzakis, E. T., and Antonarakis, S. E. (2009) Common regulatory variation impacts gene expression in a cell type-dependent manner. *Science* **325**, 1246–1250
 45. Duan, S., Huang, R. S., Zhang, W., Bleibel, W. K., Roe, C. A., Clark, T. A., Chen, T. X., Schweitzer, A. C., Blume, J. E., Cox, N. J., and Dolan, M. E. (2008) Genetic architecture of transcript-level variation in humans. *Am. J. Hum. Genet.* **82**, 1101–1113
 46. Maher, B. (2012) ENCODE: The human encyclopaedia. *Nature* **489**, 46–48
 47. [preprint] Shu, L., Zhao, Y., Kurt, Z., Byars, S. G., Tukiainen, T., Kettunen, J., Ripatti, S., Zhang, B., Inouye, M., and Makinen, V-P. (2016) Mergeomics: integration of diverse genomics resources to identify pathogenic perturbations to biological systems. *bioRxiv*. <https://doi.org/10.1101/036012>
 48. Benjamini, Y., and Hochberg, Y. (1995) Controlling the false discovery rate - a practical and powerful approach to multiple testing. *J. Roy. Stat. Soc. B Met.* **57**, 289–300
 49. Zhang, K. L., Cui, S. J., Chang, S. H., Zhang, L. Y., and Wang, J. (2010) i-GSEA4GWAS: a web server for identification of pathways/gene sets associated with traits by applying an improved gene set enrichment analysis to genome-wide association study. *Nucleic Acids Res.* **38**, W90–W95
 50. Zhu, J., Zhang, B., Smith, E. N., Drees, B., Brem, R. B., Kruglyak, L., Bumgarner, R. E., and Schadt, E. E. (2008) Integrating large-scale functional genomic data to dissect the complexity of yeast regulatory networks. *Nat. Genet.* **40**, 854–861
 51. Wang, I. M., Zhang, B., Yang, X., Zhu, J., Stepaniants, S., Zhang, C. S., Meng, Q. Y., Peters, M., He, Y. D., Ni, C., Slipetz, D., Crackower, M. A., Houshyar, H., Tan, C. M., Asante-Appiah, E., *et al.* (2012) Systems analysis of eleven rodent disease models reveals an inflammatome signature and key drivers. *Mol. Syst. Biol.* **8**, 594
 52. Yang, X., Zhang, B., Molony, C., Chudin, E., Hao, K., Zhu, J., Gaedigk, A., Suver, C., Zhong, H., Leeder, J. S., Guengerich, F. P., Strom, S. C., Schuetz, E., Rushmore, T. H., Ulrich, R. G., *et al.* (2010) Systematic genetic and genomic analysis of cytochrome P450 enzyme activities in human liver. *Genome Res.* **20**, 1020–1036
 53. Ye, J., Coulouris, G., Zaretskaya, I., Cutcutache, I., Rozen, S., and Madden, T. L. (2012) Primer-BLAST: a tool to design target-specific primers for polymerase chain reaction. *BMC Bioinform.* **13**, 134
 54. Livak, K. J., and Schmittgen, T. D. (2001) Analysis of relative gene expression data using real-time quantitative PCR and the 2(T)_{-Delta} method. *Methods* **25**, 402–408
 55. Folch, J., Lees, M., and Stanley, G. S. (1957) A simple method for the isolation and purification of total lipides from animal tissues. *J. Biol. Chem.* **226**, 497–509
 56. Diamante, G., Cely, I., Zamora, Z., Ding, J., Blencowe, M., Lang, J., Bline, A., Singh, M., Lusis, A. J., and Yang, X. (2021) Systems toxicogenomics of prenatal low-dose BPA exposure on liver metabolic pathways, gut microbiota, and metabolic health in mice. *Environ. Int.* **146**, 106260
 57. Welter, D., MacArthur, J., Morales, J., Burdett, T., Hall, P., Junkins, H., Klemm, A., Flicek, P., Manolio, T., and Hindorf, L. (2013) The NHGRI GWAS Catalog, a curated resource of SNP-trait associations. *Nucleic Acids Res.* **42**, D1001–D1006
 58. Goh, K. I., Cusick, M. E., Valle, D., Childs, B., Vidal, M., and Barabasi, A. L. (2007) The human disease network. *Proc. Natl. Acad. Sci. U. S. A.* **104**, 8685–8690
 59. Shu, L., Chan, K. H. K., Zhang, G., Huan, T., Kurt, Z., Zhao, Y., Codoni, V., Trégouët, D-A., Yang, J., and Wilson, J. G. (2017) Shared genetic regulatory networks for cardiovascular disease and type 2 diabetes in multiple populations of diverse ethnicities in the United States. *PLoS Genet.* **13**, e1007040
 60. Zhao, Y., Blencowe, M., Shi, X., Shu, L., Levian, C., Ahn, I. S., Kim, S. K., Huan, T., Levy, D., and Yang, X. (2019) Integrative genomics analysis unravels tissue-specific pathways, networks, and key regulators of blood pressure regulation. *Front. Cardiovasc. Med.* **6**, 21
 61. Zhao, Y., Jhamb, D., Shu, L., Arneson, D., Rajpal, D. K., and Yang, X. (2019) Multi-omics integration reveals molecular networks and regulators of psoriasis. *BMC Syst. Biol.* **13**, 8
 62. Krishnan, K. C., Kurt, Z., Barrere-Cain, R., Sabir, S., Das, A., Floyd, R., Vergnes, L., Zhao, Y., Che, N., and Charugundla, S. (2018) Integration of multi-omics data from mouse diversity

- panel highlights mitochondrial dysfunction in non-alcoholic fatty liver disease. *Cell Syst.* **6**, 103–115.e7
63. Hewing, B., and Landmesser, U. (2015) LDL, HDL, VLDL, and CVD prevention: lessons from genetics? *Current Cardiol. Rep.* **17**, 56
 64. Santos-Gallego, C. G. (2015) HDL: quality or quantity? *Atherosclerosis*. **243**, 121–123
 65. McGillicuddy, F. C., Chiquoine, E. H., Hinkle, C. C., Kim, R. J., Shah, R., Roche, H. M., Smyth, E. M., and Reilly, M. P. (2009) Interferon γ attenuates insulin signaling, lipid storage, and differentiation in human adipocytes via activation of the JAK/STAT pathway. *J. Biol. Chem.* **284**, 31936–31944
 66. Parker, B. L., Calkin, A. C., Seldin, M. M., Keating, M. F., Tarling, E. J., Yang, P., Moody, S. C., Liu, Y., Zerenturk, E. J., and Needham, E. J. (2019) An integrative systems genetic analysis of mammalian lipid metabolism. *Nature* **567**, 187
 67. Zizola, C., Frey, S. K., Jitngarmkusol, S., Kadereit, B., Yan, N., and Vogel, S. (2010) Cellular retinol-binding protein type I (CRBP-I) regulates adipogenesis. *Mol. Cell. Biol.* **30**, 3412–3420
 68. Schöffler, A., and Schölmerich, J. (2010) Innate immunity and adipose tissue biology. *Trends Immunol.* **31**, 228–235
 69. Vance, J. E. (2014) MAM (mitochondria-associated membranes) in mammalian cells: lipids and beyond. *Biochim. Biophys. Acta Mol. Cell Biol. Lipids*. **1841**, 595–609
 70. Liu, J. P., Tang, Y., Zhou, S. F., Toh, B. H., McLean, C., and Li, H. (2010) Cholesterol involvement in the pathogenesis of neurodegenerative diseases. *Mol. Cell Neurosci.* **43**, 33–42
 71. Jeong, H., Mason, S. P., Barabasi, A. L., and Oltvai, Z. N. (2001) Lethality and centrality in protein networks. *Nature*. **411**, 41–42
 72. Zhang, B., Gaiteri, C., Bodea, L. G., Wang, Z., McElwee, J., Podtezhnikov, A. A., Zhang, C., Xie, T., Tran, L., Dobrin, R., Fluder, E., Clurman, B., Melquist, S., Narayanan, M., Suver, C., *et al.* (2013) Integrated systems approach identifies genetic nodes and networks in late-onset Alzheimer's disease. *Cell*. **153**, 707–720
 73. Kurt, Z., Barrere-Cain, R., LaGuardia, J., Mehrabian, M., Pan, C., Hui, S. T., Norheim, F., Zhou, Z., Hasin, Y., and Lusi, A. J. (2018) Tissue-specific pathways and networks underlying sexual dimorphism in non-alcoholic fatty liver disease. *Biol. Sex Diff.* **9**, 46
 74. Knox, C., Law, V., Jewison, T., Liu, P., Ly, S., Frolkis, A., Pon, A., Banco, K., Mak, C., Neveu, V., Djoumbou, Y., Eisner, R., Guo, A. C., and Wishart, D. S. (2011) DrugBank 3.0: a comprehensive resource for 'Omics' research on drugs. *Nucleic Acids Res.* **39**, D1035–D1041
 75. Yue, W. W., and Oppermann, U. (2011) High-throughput structural biology of metabolic enzymes and its impact on human diseases. *J. Inherit. Metab. Dis.* **34**, 575–581
 76. Maitland-van der Zee, A. H., Peters, B. J. M., Lynch, A. I., Boerwinkle, E., Arnett, D. K., Cheng, S., Davis, B. R., Leidencker-Foster, C., Ford, C. E., and Eckfeldt, J. H. (2009) The effect of nine common polymorphisms in coagulation factor genes (F2, F5, F7, F12 and F13) on the effectiveness of statins: the GenHAT study. *Pharmacogenet. Genom.* **19**, 338–344
 77. Ference, B. A., Yoo, W., Alesh, I., Mahajan, N., Mirowska, K. K., Mewada, A., Kahn, J., Afonso, L., Williams, K. A., and Flack, J. M. (2012) Effect of long-term exposure to lower low-density lipoprotein cholesterol beginning early in life on the risk of coronary heart disease: a mendelian randomization analysis. *J. Am. Coll. Cardiol.* **60**, 2631–2639
 78. Guilhaume, A., Virbasius, J. V., Puri, V., and Czech, M. P. (2008) Adipocyte dysfunctions linking obesity to insulin resistance and type 2 diabetes. *Nat. Rev. Mol. Cell Biol.* **9**, 367–377
 79. Voight, B. F., Peloso, G. M., Orho-Melander, M., Frikke-Schmidt, R., Barbalic, M., Jensen, M. K., Hindy, G., Holm, H., Ding, E. L., Johnson, T., Schunkert, H., Samani, N. J., Clarke, R., Hopewell, J. C., Thompson, J. F., *et al.* (2012) Plasma HDL cholesterol and risk of myocardial infarction: a mendelian randomisation study. *Lancet*. **380**, 572–580
 80. Memisogullari, R., and Bakan, E. (2004) Levels of ceruloplasmin, transferrin, and lipid peroxidation in the serum of patients with Type 2 diabetes mellitus. *J. Diabetes Complicat.* **18**, 193–197
 81. Volkmar, M., Dedeurwaerder, S., Cunha, D. A., Ndlovu, M. N., Defrance, M., Deplus, R., Calonne, E., Volkmar, U., Igoillo-Esteve, M., Naamane, N., Del Guerra, S., Masini, M., Bugliani, M., Marchetti, P., Cnop, M., *et al.* (2012) DNA methylation profiling identifies epigenetic dysregulation in pancreatic islets from type 2 diabetic patients. *EMBO J.* **31**, 1405–1426
 82. Blencowe, M., Karunanayake, T., Wier, J., Hsu, N., and Yang, X. (2019) Network modeling approaches and applications to unravelling non-alcoholic fatty liver disease. *Genes*. **10**, 966
 83. Chen, L., Yao, Y., Jin, C., Wu, S., Liu, Q., Li, J., Ma, Y., Xu, Y., and Zhong, Y. (2019) Integrative genomic analysis identified common regulatory networks underlying the correlation between coronary artery disease and plasma lipid levels. *BMC Cardiovasc. Disord.* **19**, 1–10
 84. Lamina, C., Friedel, S., Coassin, S., Rueedi, R., Yousri, N. A., Seppälä, I., Gieger, C., Schönherr, S., Forer, L., and Erhart, G. (2016) A genome-wide association meta-analysis on apolipoprotein A-IV concentrations. *Hum. Mol. Genet.* **25**, 3635–3646